Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on July 28, 2022. The filing primarily addresses corporate governance changes and discloses related-party transactions involving a newly elected director. Note: The input metadata references "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics and Transactions
The filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins. Instead, it details specific capital transactions involving the new director, Mr. John Peter Gutfreund, and his affiliated entities:
- Preferred Stock Offer (April 13, 2022): Mr. Gutfreund purchased 1,176.48 shares of Series A Convertible Preferred Stock for a total of $1,000,000. The purchase price was $850 per share (including an original issue discount to a stated value of $1,000).
- Underwritten Offer (April 13, 2022): Halle Special Situations Fund LLC, managed by Mr. Gutfreund, purchased 7,129,456 shares of common stock and warrants for an aggregate price of $9,500,000.12.
- Warrant Details: The underwritten offer included 7,129,456 warrants to purchase up to 3,564,728 shares of common stock.
Material Changes and Governance
Board Appointment: Effective July 28, 2022, the Board elected John Peter Gutfreund as a director. His term expires at the 2023 Annual Meeting of Shareholders. He has been appointed to the Finance Committee (serving as Chair) and the Compensation Committee and is deemed an independent director.
Related Party Transactions: The filing discloses that Mr. Gutfreund has a direct material interest in the April 2022 financing rounds. Prior to these transactions, Mr. Gutfreund and affiliated entities held no common stock of the Company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future business performance. The primary risk disclosure relates to the related-party nature of the financing transactions, where the new director and his firm were significant investors in the Company's recent capital raises.
Investor Verification Checklist
- Verify the exact conversion terms and liquidation preferences of the Series A Convertible Preferred Stock purchased by Mr. Gutfreund.
- Confirm the exercise price and expiration date of the 2022 Warrants issued to Halle Special Situations Fund LLC.
- Review the Company's 2022 Proxy Statement (filed June 8, 2022) for details on the director compensation plan applicable to Mr. Gutfreund.
- Assess the dilution impact of the 7,689,542 shares of common stock issuable upon conversion of the Preferred Stock and the 3,564,728 shares issuable upon exercise of the warrants.